SEARCH

SEARCH BY CITATION

References

  • 1
    Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352:13431356.
  • 2
    Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23:683747.
  • 3
    Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2012; (8)CD002062.
  • 4
    Mehndiratta MM, Hughes RA. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2012; (9)CD003906.
  • 5
    Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev 2008; (1)CD006264.
  • 6
    Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; (12)CD006921.
  • 7
    Tumani H. Corticosteroids and plasma exchange in multiple sclerosis. J Neurol 2008; 255 (Suppl. 6):3642.
  • 8
    Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352:14981504.
  • 9
    Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343:898904.
  • 10
    Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56:14961504.
  • 11
    Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56:15051513.
  • 12
    Clerico M, Faggiano F, Palace J, Rice G, Tintore M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008; (2)CD005278.
  • 13
    La Mantia L, Vacchi L, Di Pietrantonj C et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev 2012; (1)CD005181.
  • 14
    Rice GP, Incorvaia B, Munari L et al. Interferon in relapsing–remitting multiple sclerosis. Cochrane Database Syst Rev 2001; (4)CD002002.
  • 15
    Kappos L, Freedman MS, Polman CH et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8:987997.
  • 16
    Kappos L, Freedman MS, Polman CH et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370:389397.
  • 17
    Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:12421249.
  • 18
    Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352:14911497.
  • 19
    Comi G, Martinelli V, Rodegher M et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:15031511.
  • 20
    La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2010; (5)CD004678.
  • 21
    Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:12681276.
  • 22
    Biogen Idec. Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis. Weston, MA: Biogen Idec; 2013.
  • 23
    Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53:5761.
  • 24
    Hughes RA, Gorson KC, Cros D et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74:651657.
  • 25
    Mahdi-Rogers M, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013; (6)CD003280.
  • 26
    Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. A multinational, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy, safety, and tolerability of glatiramer acetate 40 mg injection three times a week in subjects with RRMS: efficacy and safety results of the GALA study. Abstract, 65th American Academy of Neurology Annual Meeting. 2013.
  • 27
    Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367:20152025.
  • 28
    Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004; 63:20282033.
  • 29
    Visser LH, Beekman R, Tijssen CC et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004; 10:8991.
  • 30
    Fazekas F, Lublin FD, Li D et al. Intravenous immunoglobulin in relapsing–remitting multiple sclerosis: a dose-finding trial. Neurology 2008; 71:265271.
  • 31
    Hommes OR, Sorensen PS, Fazekas F et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364:11491156.
  • 32
    Filippi M, Rocca MA, Pagani E et al. European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 2004; 61:14091412.
  • 33
    Hughes R, Bensa S, Willison H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:195201.
  • 34
    Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56:445449.
  • 35
    Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119:10671077.
  • 36
    Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7:136144.
  • 37
    Nobile-Orazio E, Cocito D, Jann S et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11:493502.
  • 38
    Leger JM, De Bleecker JL, Sommer C et al. Efficacy and safety of Privigen((R)) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). J Peripher Nerv Syst 2013; 18:130140.
  • 39
    Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007; (4)CD003982.
  • 40
    Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev 2004; (2)CD003208.
  • 41
    Michel L, Vukusic S, De Seze J et al. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry 2013 http://dx.doi.org/10.1136/jnnp-2013-305298.
  • 42
    Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol 2010; 9:299308.
  • 43
    Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013; (5)CD002127.
  • 44
    Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:20182025.
  • 45
    Rommer PS, Zettl UK, Kieseier B et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol 2014; 175:397407.
  • 46
    Winkelmann A, Loebermann M, Reisinger EC, Zettl UK. Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol 2014; 175:425438.
  • 47
    La Mantia L, Milanese C, Mascoli N, D'Amico R, Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 2007; (1)CD002819.
  • 48
    O'Connor P, Wolinsky JS, Confavreux C et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365:12931303.
  • 49
    Sanofi/Genzyme. Genzyme reports positive top-line results of TOWER, a pivotal Phase III trial for AUBAGIOTM* (teriflunomide) in relapsing multiple sclerosis. Sanofi/Genzyme. 2012.
  • 50
    He D, Xu Z, Dong S et al. Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev 2012; (12)CD009882.
  • 51
    Joshi G, Johnson JA. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov 2012; 7:218229.
  • 52
    Gold R, Kappos L, Arnold DL et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367:10981107.
  • 53
    Fox RJ, Miller DH, Phillips JT et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:10871097.
  • 54
    Phillips JT, Fox EJ, Selmaj K et al. Long-term safety and tolerability of oral BG-12 (dimethyl fumarate) in relapsing–remitting multiple sclerosis: interim results from ENDORSE. 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis. 2012.
  • 55
    Comi G, Jeffery D, Kappos L et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366:10001009.
  • 56
    TEVA Pharmaceutical Industries, Inc. Results of Phase III BRAVO trial reinforce unique profile of laquinimod for multiple sclerosis treatment. Tikva, Israel: TEVA; 2011.
  • 57
    TEVA Pharmaceutical Industries, Inc. First patient enrolled in third Phase III of oral laquinimod for relapsing–remitting multiple sclerosis. Tikva, Israel: TEVA; 2013.
  • 58
    Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899910.
  • 59
    Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911923.
  • 60
    Miller DH, Weber T, Grove R et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2012; 11:131139.
  • 61
    Wolf C, Menge T, Stenner MP et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2010; 67:881883.
  • 62
    Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366:18701880.
  • 63
    Kappos L, Radue EW, O'Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387401.
  • 64
    Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402415.
  • 65
    Cohen JA, Coles AJ, Arnold DL et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380:18191828.
  • 66
    Coles AJ, Twyman CL, Arnold DL et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380:18291839.
  • 67
    Marsh EA, Hirst CL, Llewelyn JG et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257:913919.
  • 68
    Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008; 358:676688.
  • 69
    Munch C, Anagnostou P, Meyer R, Haas J. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 2007; 256:100102.
  • 70
    Briani C, Zara G, Zambello R, Trentin L, Rana M, Zaja F. Rituximab-responsive CIDP. Eur J Neurol 2004; 11:788.
  • 71
    Benedetti L, Briani C, Franciotta D et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82:306308.
  • 72
    Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 2010; 3:93105.
  • 73
    Kappos L, Li D, Calabresi PA et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378:17791787.
  • 74
    Hoffmann-LaRoche. Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years. Basel, Switzerland: Hoffmann-LaRoche; 2011.
  • 75
    GlaxoSmithKline. Genmab announces results of ofatumumab Phase II study in multiple sclerosis. Princeton, NJ: GlaxoSmithKline. 2010.
  • 76
    GlaxoSmithKline. GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications. Princeton, NJ: GlaxoSmith Kline. 2010.
  • 77
    Wynn D, Kaufman M, Montalban X et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9:381390.
  • 78
    Gold R, Giovannoni G, Selmaj K et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:21672175.
  • 79
    Biogen Idec. Biogen Idec and Abbott announce enrollment of first patient in global Phase III study of daclizumab for relapsing–remitting multiple sclerosis. Weston, MA: Biogen Idec. 2010.
  • 80
    Filippini G, Del Giovane C, Vacchi L et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013; (6)CD008933.
  • 81
    Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29:558565.